Growth Metrics

Volitionrx (VNRX) EBITDA Margin (2019 - 2025)

Volitionrx's EBITDA Margin history spans 9 years, with the latest figure at 1704.28% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 122380.0% year-over-year to 1704.28%; the TTM value through Dec 2025 reached 1556.41%, up 87030.0%, while the annual FY2025 figure was 1894.44%, 30386.0% up from the prior year.
  • EBITDA Margin reached 1704.28% in Q4 2025 per VNRX's latest filing, down from 1000.67% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 1000.67% in Q3 2025 to a low of 61692.56% in Q4 2021.
  • Average EBITDA Margin over 5 years is 11603.96%, with a median of 5013.92% recorded in 2023.
  • Peak YoY movement for EBITDA Margin: soared 190771026bps in 2021, then skyrocketed 26598bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 61692.56% in 2021, then surged by 90bps to 6201.93% in 2022, then surged by 42bps to 3605.06% in 2023, then rose by 19bps to 2928.08% in 2024, then surged by 42bps to 1704.28% in 2025.
  • Per Business Quant, the three most recent readings for VNRX's EBITDA Margin are 1704.28% (Q4 2025), 1000.67% (Q3 2025), and 1694.19% (Q2 2025).